Teclistamab-cqyv

Indications and Usage

Tecvayli™ (teclistamab‑cqyv) is indicated for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor,  an immunomodulatory agent and an anti-CD38 monoclonal antibody. 

This indication is approved under accelerated approval based on response rate. Continued approval for this indication may be  contingent upon verification and description of clinical benefit in confirmatory trial(s).

Side effects needing medical attention

The most common adverse reactions were fever, cytokine release syndrome, musculoskeletal pain, injection site reaction, fatigue, upper respiratory tract infection, nausea, headache, pneumonia, and diarrhea. The most common laboratory abnormalities were decreased lymphocytes, decreased neutrophils, decreased white blood cells, decreased hemoglobin, and decreased platelets.